NMS·Healthcare·$481M·#454 / 520 in Healthcare
EDIT Editas Medicine, Inc.
23HIGH RISK
CATEGORY BREAKDOWN
GROWTH41
QUALITY0
STABILITY36
VALUATION36
GOVERNANCE1
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+25.4%
41
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
11 months
33
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
66.3%
40
< 25% strong
Price / Sales
Market cap relative to trailing revenue
12.4x
36
< 3x strong
Rule of 40
Growth rate plus operating margin
-220
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.2%
1
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+75.6%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE EDIT WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when EDIT's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.